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Abstract. Inadequate pain management
but also inappropriate use of analgesics in
early infancy has negative effects on neurodevelopmental outcome. As a consequence,
neonatal pain management is still in search
for the Holy Grail. At best, effective pain
management is based on prevention, assessment, and treatment followed by a re-assessment of the pain to determine if additional
treatment is still necessary. Unfortunately,
epidemiological observations suggest that
neonates are undergoing painful procedures
very frequently, unveiling the need for effective preventive, non-pharmacological strategies. In addition, assessment is still based on
validated, multimodal, but subjective pain
assessment tools. Finally, in neonatal intensive care units, there is a shift in clinical
practices (e.g., shorter intubation and ventilation), and this necessitates the development and validation of new pharmacological
treatment modalities. To illustrate this, a shift
in the use of opioids to paracetamol has occurred and short-acting agents (remifentanil,
propofol) are more commonly administered
to neonates. In addition to these new modalities and as part of a more advanced approach
of the developmental pharmacology of analgesics, pharmacogenetics also emerged as a
tool for precision medicine in neonates. To
assure further improvement of neonatal pain
management the integration of pharmacogenetics with the usual covariates like weight,
age and/or disease characteristics is needed.

Introduction: on how we act
and what we know
Inadequate pain management in neonatal
life impairs neurodevelopmental outcome.
It alters pain thresholds, physiological responses and stress- or pain-related behavior

beyond early infancy [1, 2, 3, 4]. Therefore,
pain management in neonates should not
just be driven by ethics or empathy but it
should be viewed as part of normal medical
and nursing care. At the same time, there are
emerging animal experimental and human
epidemiological data that show an association between the exposure to analgesics and
impaired neurodevelopmental outcome [5,
6, 7]. As a consequence, the management of
neonatal pain remains in search of a new balance because these conflicting observations
are the main drivers to tailor our current practices. To reach this new balance new treatment
modalities, including non-pharmacological
and pharmacological strategies, will need to
be developed and validated [7, 8, 9].

Epidemiology
An additional argument in support of the
need for new treatment modalities, including
non-pharmacological interventions, is that
epidemiological observations provide evidence for shifts in neonatal pain management
practices [10]. In Table 1, we summarized
observations on pain management practices
in (pre)term neonates in the first 14 days of
postnatal life [11, 12, 13]. Compared to the
cohorts of 2001 and 2005 – 2006, the Rotterdam group (2009) documented a statistically
significant, but clinically modest decrease
in the number of painful procedures (11 instead of 14/day) [11, 13], with more routine
use and integration of non-pharmacological
interventions, and a decrease in opioid use in
ventilated newborns [13].

515

Neonatal pain management

Table 1. The incidence of painful procedures and its management as reported in different cohorts of
(pre)term neonates. All studies collected data in the first 14 days of postnatal life [11, 12, 13].
Time interval of data collection
Number of patients
Gestational age (weeks)
Patient days
Number of procedures, total
Number of procedures, per day
Pharmacological analgesia (%)

Rotterdam [11]
2001
151
32.4 (SD 4.5)
1,375
19,674
14.3 (SD 4.0)
60.3%

Pain management in neonates is not
only limited to pharmacological
interventions
Non-pharmacological interventions stress
the fact that not only what, but also how we
perform painful procedures matters [8, 9,
14]. The focus needs to be on less invasive
techniques, preventive strategies, or complementary techniques [14, 15]. Environmental
(light or noise exposure), behavioral (positioning, handling, swaddling), and non-pharmacological (sucrose, breastfeeding, pacifier,
non-nutritive sucking) interventions prevent,
alleviate, or even eliminate pain. Adaptations
of procedural practices may be a very powerful approach to prevent pain. Such strategies
also cover the use of central venous catheters
instead of multiple peripheral perfusions, individualized monitoring techniques (blood
pressure measurement interval, vital signs
registration), adapted nursing techniques
(e.g., frequency of endotracheal suctioning, skin and wound care, tape and wound
dressing) or promoting skin-to-skin contact
between newborn and parents [8, 9, 14, 15].

Assessment is still subjective and
thus suboptimal
The absence of verbalization is very
likely one of the most important thresholds
for the proper diagnosis and management of
neonatal pain [16, 17, 18]. Pain in the newborn is not easily recognized and remains
commonly under- or untreated. Pain assessment is still based on validated, multimodal,
but subjective pain assessment tools, like
the COMFORTneo score [17]. Until more
advanced equipment becomes available to
quantify pain, we should apply such a validated pain assessment tool in clinical prac-

Paris [12]
2005 – 2006
430
33 (SD 4.6)
3,598
42,413
16 (SD 9)
57.1%

Rotterdam [13]
2009
175
31.6 (range 24 – 41)
1,730
21,076
11.4 (SD 5.7)
36.5%

tice and train health care providers in using
these tools in a standardized way to guarantee a reasonable interobserver variation in
the assessment of pain in neonates [18, 19].

Developmental pharmacology
of analgesics in neonates:
a moving target
The general paradigm on pain management in neonates is driven by assessment,
titration of a given intervention (non-pharmacological, pharmacological, or both) and
subsequent re-assessment [3, 8]. Clinical
pharmacology aims to predict (side) effects
of compound specific pharmacokinetics
(PK) and pharmacodynamics (PD) at the
level of the population or – preferably – the
individual. These general concepts of clinical pharmacology obviously also apply to
analgesics in neonates, but their maturational physiology and the associated variability within the population warrant a tailored
approach [20, 21, 22]. PK in early infancy
display extensive intra- and inter-individual
variability. This can in part be explained by
e.g., maturational changes in body composition, protein binding, and compartment sizes
during infancy. Similar, drug-related metabolic processes mature in an enzyme-specific
pattern while renal function also displays an
age-dependent increase in clearance. From a
clinical pharmacology perspective, the consequence of such a dynamic setting is extensive variability in early infancy [20, 21, 22].
This dynamic setting further stresses the
need to perform focused studies on new analgesics introduced in the neonatal unit [22].
Moreover, it also means that new covariates
emerging in other populations such as phar-
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Figure 1. Individual clearance (L/kg/h) estimates
in 30 (pre)term neonates following a single intravenous propacetamol (10 – 20 mg/kg paracetamol
equivalent) administration show a modest increase
with increasing weight (median clearance < 2 kg
0.123 to 0.16 L/kg/h in cases > 2 kg) (X-axis:
weight, in g; Y-axis: paracetamol clearance, in L/
kg/h) [28].

macogenetics may further explain in part the
variability observed in neonates, but need to
be integrated with other maturational covariates like weight or age. We will first discuss
the PK/PD of intravenous paracetamol and
two short acting compounds (remifentanil,
propofol) since these drugs have recently
been introduced in neonatal intensive care
units. Then we will provide guidance on how
to integrate pharmacogenetics as another covariate to improve the predictability of individual PK or PD in early infancy.

Shift from opioids to paracetamol
In an attempt to avoid or reduce opioid
exposure, a shift to administer paracetamol
has occurred, hugely facilitated by the availability of an intravenous formulation [23, 24,
25, 26, 27]. Despite the fact that intravenous
paracetamol is still used off label in specific
subpopulations (e.g., limited to term neonates, or, under 2 years of age in the United
States), these formulations are increasingly used in (pre)term neonates [23, 26]. In
adults, paracetamol is metabolized by the
liver to paracetamol-glucuronide (47 – 62%)
and paracetamol-sulphate (25 – 36%), and
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subsequently eliminated by the renal route.
Only 1 – 4% is excreted unchanged in urine,
and ~ 8 – 10% of paracetamol is oxidized
to 3-hydroxy-paracetamol and the (hepatic)
toxic metabolite N-acetyl-p-benzoquinoneimine (NAPQI). In neonates, paracetamol
clearance is lower, and its variability is
mainly explained by weight. This is further
illustrated in Figure 1, where we plotted the
individual paracetamol clearance estimates
for 30 (pre)term neonates following a single
intravenous paracetamol administration [28].
Similarly, also the formation clearance to
paracetamol-glucuronide and paracetamolsulphate, and primary renal elimination of
paracetamol is mainly related to weight [29].
However, in contrast to the observations in
adults, sulphation and not glucuronidation
is the most important route of elimination in
neonates [29].
The currently available evidence on the
efficacy of paracetamol as analgesic supports
the use of paracetamol for minor to moderately severe pain syndromes in early infancy
[30]. Moreover, paracetamol has a clinically
relevant opioid-sparing effect (66%) in neonates after major non-cardiac surgery [24].
In contrast, there is only a very limited analgesic effect of paracetamol when used for
procedural (e.g., heel lancing) pain relief
[23]. Short-term tolerance (hepatic, hemodynamics) has been described [31, 32], indicating no signs of hepatic intolerance during
and after repeated administrations of intravenous paracetamol [31]. In contrast to the
negative hemodynamic effects in adult intensive care patients, hemodynamic side effects of intravenous paracetamol in neonates
are very modest [32]. Besides these shortterm outcome side effects, there are some
population-specific side effects that warrant
focused attention. Recent epidemiological
data showed a possible link between the
(over) use of paracetamol during pregnancy
or early infancy and immune deviations or
neurodevelopmental problems (e.g., autism)
[23]. Causality is still very questionable and
for sure not yet proven, but pharmacovigilance is warranted to explore the potential association between paracetamol exposure and
these outcome variables.
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The need to generate knowledge
of short-acting agents in
neonates
Taking the shift towards less invasive
neonatal care (e.g., insure procedure, i.e.,
intubation – surfactant administration – extubation instead of prolonged mechanical
ventilation) into account, remifentanil and
propofol have been introduced in neonatal
intensive care [2, 8, 9, 33, 34].
Remifentanil hydrochloride is a shortacting, µ-receptor opioid agonist. It achieves
its peak analgesic effect within a minute
of administration, 3 – 4 times faster when
compared to fentanyl and much faster when
compared to morphine [33]. Remifentanil
undergoes metabolic clearance by plasma
esterases, resulting in predictable clearance,
irrespective of renal or liver dysfunction, and
the plasma esterase activity is already quite
mature at birth [35]. Its pharmacological profile seems suited for short procedural analgesia [36, 37, 38, 39, 40]. In neonates, this
compound has mainly been used for short
procedures like endotracheal intubation, laser surgery for retinopathy of prematurity or
for insertion of a percutaneous intravenous
central catheter with anecdotal experience
during major surgery or mechanical ventilation [36, 37, 38, 39, 40]. Because of its rapid
clearance, clinicians must be aware that the
analgesic effects disappear very soon after
discontinuation of remifentanil [33]. Other
issues to consider are potential hyperalgesia,
fast appearance of tolerance, and the risk of
chest rigidity [33].
Propofol (2,6 di-isopropylphenol) is a
highly lipophilic compound [34]. Propofol
exhibits rapid distribution to the subcutaneous fat and the central nervous system compartments with subsequent redistribution to
the blood compartment and metabolic clearance [34, 41]. Because propofol is not soluble
in water, propofol clearance is exclusively
through metabolic clearance [41, 42]. Although multiple hepatic and extrahepatic human cytochrome (CYP) P450 isoforms (hydroxylation, mainly CYP2B6) are involved
in propofol metabolism, glucuronidation is
the major metabolic pathway after a single
intravenous bolus in adults [41, 42, 43]. In
contrast, propofol clearance in neonates is
much lower, and mainly driven by postnatal

age [43]. Interestingly and based on 24 hours
urine collections, not glucuronidation but
hydroxylation is the most important route of
propofol metabolism in the first 10 days of
postnatal life [42, 43]. In neonates, there is
reported experience with intravenous bolus
propofol administration to facilitate endotracheal intubation, but there is important variability in clinical characteristics, outcome
criteria, comedication and doses evaluated in
the different studies [34, 44, 45]. Similarly,
there is conflicting information on the magnitude of hemodynamic (side) effects of propofol in (pre)term neonates. In a recent Cochrane review, Shah et al. [34] concluded that
regarding the use of propofol in neonates, no
practice recommendations could be made yet.

How to integrate
pharmacogenetics into
developmental pharmacology
of analgesics
The emerging field of pharmacogenetics
as a tool for personalized medicine – including pain management – reflects the notion
that a specific (side) effect is not at random
distributed in a specific population [46]. This
obviously also holds promises for personalized pain management in young infants, but
in addition to the usual covariates like weight,
age and/or disease characteristics [22, 47]. We
hereby strongly recommend the integration of
pharmacogenetics as an additional covariate
to improve individual PK or PD predictions in
early infancy [22, 47]. In this special issue on
various aspects of pain and its management,
pharmacogenetics is repeatedly suggested to
contribute to the PK/PD variability of analgesics. We will illustrate the complex interaction
between maturational changes and polymorphisms comparing propofol and tramadol
PK observations in early infancy. In essence,
the utility of pharmacogenetics as predicting
covariate is limited to periods during development in which genotype-phenotype concordance already exists [22, 47]. To illustrate
this, a literature search on specific genetic
polymorphisms related to PK/PD of analgesics in adults has been performed. Based on
the findings of this search the relevance of
specific genetic polymorphisms for optimizing analgesia in neonates will be explored.
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route of propofol metabolic clearance in early
neonatal life [43]. These in-vivo observations
are in line with the available in vitro observations on UGT1A9 ontogeny describing a
progressive increase in activity throughout
infancy [50].

Figure 2. The impact of age (preterm (< 37 weeks)
or term) and the CYP2D6 activity score (either 1, 2,
or 3) on the plasma log M/M1 value. A lower M/M1
value hereby reflects a higher CYP2D6 activity, depending on both age and genetic polymorphisms.
Individual plasma log M/M1 values were extracted from an earlier published dataset on tramadol
disposition in neonates. There were no cases with
a CYP2D6 activity score of 3 in the preterm age
cohort. (M = tramadol; M1 = O-desmethyltramadol)
(X-axis: preterm (< 37 week) or term (≥ 37 week)
cases, Y-axis: plasma log M/M1 value) [49].

Maturational drug metabolism
and polymorphisms: is
“concordance” already present?
Besides age or weight as maturational
covariates, genetic polymorphisms in drugmetabolizing enzymes, transporters or receptors may further contribute to the variability
in PK/PD of analgesic drugs in early infancy
if concordance already exists [23, 48]. Concordance is hereby restricted to the presence
of a phenotype-genotype linkage similar to
what is known in adults. Sufficient maturational driven phenotypic activity is needed
before an impact of polymorphisms can be
explored. We therefore try to illustrate this
by comparing available observations on propofol and tramadol disposition [41, 42, 49].
Glucuronidation is the major metabolic pathway after a single intravenous
bolus of propofol in adults. As a consequence, UGT1A9 promotor polymorphisms
(UGT1A9-331C/T) affect propofol clearance
in adults [41]. However, this can’t be directly
translated to the neonate because not glucuronidation, but hydroxylation is the major

In contrast, concordance for the impact
of cytochrome P450 enzyme 2D6 (CYP2D6)
polymorphism on tramadol metabolism in
early life has been described. Tramadol is a
racemic mixture of two enantiomers, (+)-tramadol and (–)-tramadol hydrochloride [46,
49]. The analgesic effects of tramadol are
mediated through noradrenaline re-uptake
inhibition, increased serotonin release and
decreased serotonin re-uptake in the spinal cord. Tramadol itself also has a weak
µ-opioid receptor effect. Tramadol (M) is

metabolized by cytochrome P450 enzyme
2D6 (CYP2D6) to the active metabolite
(µ-opioid receptor agonist) O-desmethyltramadol (M1) and the inactive metabolite
N-desmethyltramadol (M2) through cytochrome P450 3A4 and 2B6 (CYP3A4 and
CYP2B6) [46, 49]. In adults, phenotypic
M1 formation is more pronounced compared
to M2 formation, but this ratio depends on
CYP2D6 polymorphisms, quantified by the
CYP2D6 activity score. Consequently, CYP2D6 polymorphisms result in differences
in analgesia through differences in M1 formation. Besides CYP2D6 polymorphisms,
variability in M1 disposition has been linked
to maturational changes (weight, age), comedication (e.g., drug-drug interactions) or comorbidity (e.g., renal impairment) [46, 49].
The complex interaction between maturational changes and CYP2D6 polymorphisms in early infancy has been illustrated
in a dataset of 57 cases exposed to continuous intravenous tramadol [46, 49]. In this dataset, there was a significant decrease in plasma log M/M1 with an increasing CYP2D6
activity score, reflecting higher phenotypic
CYP2D6 activity. In a forward multiple
regression model, it was concluded that
postmenstrual age and CYP2D6 polymorphisms determined O-demethylation activity in (pre)term neonates and young infants.
Figure 2 illustrates the impact of both age
(preterm vs. term cases) and CYP2D6 activity score (either 1, 2, or 3) on the plasma log
M/M1 values, based on the earlier mentioned
dataset in young infants [46, 49].
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The absence of concordance for propofol
but its presence for tramadol reflect different patterns of maturational activity of specific isoenzymes with a much more delayed
phenotypic activity for glucuronidation
(UGT1A9) as compared to demethylation
(CYP2D6). The utility of pharmacogenetics
as predicting covariate is hereby limited to
periods during development in which genotype-phenotype concordance already exists,
and is mainly driven by observations initially
reported in adults.

Are polymorphisms linked to
the PK/PD of analgesics in
adults already of relevance in
perinatal life?
In this section we like to provide an overview of the impact of specific genetic polymorphisms linked to the PK/PD of analgesics
in adults. Based on the findings of this search,
the available evidence on the relevance of
specific genetic polymorphisms to optimize
analgesia in neonates will be explored. We
will hereby consider polymorphisms related
to drug metabolizing enzymes, drug transporters, and drug targets.

Drug-metabolizing enzymes
Inter-individual variability exists in both
phase I and phase II drug metabolism, and
this variability can in part be explained by
genetic polymorphisms. It may result in differences in either effects (e.g., concentrations, level of analgesia) or sideeffects (e.g.,
sedation, toxicity).
The tramadol illustration earlier mentioned hereby provides the impact of
CYP2D6 polymorphism on metabolic clearance to M1 in neonates, in line with similar observations in adults for tramadol or
codeine [46, 49]. In the specific setting of
breastfeeding, maternal CYP2D6 ultrafast
metabolizer status – especially when combined with UGT2B7 *2/*2 polymorphism –
results in higher exposure and an increased
risk for central nervous system depression
[51]. In contrast, CYP2C8 and CYP2C9
polymorphisms could not explain the variability in patent ductus closure during ibu-

profen administration in preterm neonates
[52]. Similarly, CYP2C8 and CYP2C9 polymorphisms had no effect on the relative infant dose (all < 1%) through breastfeeding in
mothers treated with ibuprofen [53]. An association between CYP3A5 polymorphisms
(higher drug metabolism) and paracetamolinduced liver toxicity has been described
in adults [54]. This is unlikely in neonates,
because the overall phenotypic CYP3A5 in
early infancy is much lower [20, 21, 22].
If we further focus on phase II processes, Matic et al. [55] recently described the
impact of UGT2B7 polymorphisms on the
morphine-3-glucuronide/morphine ratio following a single bolus administration of morphine (0.3 mg/kg) in preterm neonates. Since
sulphation activity is already more prominent, it seems more appropriate to explore
these polymorphisms. Sulphotransferase enzymes catalyze sulphate conjugation, including paracetamol sulphation. As explored by
Leeder et al. [48], exposure to paracetamol
during pregnancy has been associated with
a modest increase in the risk (RR 1.5 – 1.7)
of gastroschisis in the infant. Based on invitro liver cytosol preparations, it has been
suggested that paracetamol sulphation by
the fetus might be linked with this increased
incidence of gastroschisis. Clearly, further
investigations into the genetic variability in
both maternal (SULT1A1, SULT2A1) and
fetal (SULT1A3/4) sulfation might shed
more light on this association [48].
Drug transporters
Membrane transporters are crucial in the
transport of compounds, and subsequently
also mediate the uptake, regional distribution, and excretion of different compounds,
including analgesics and its metabolites.
Compared to the knowledge on the ontogeny of drug metabolizing enzymes, data on
the maturation of human drug transporter
expression and activity is still much more
limited, but was recently summarized [47].
In fact, these authors also suggest to explore
pharmacogenetic concordance in early infancy and other age cohorts to learn more about
their ontogeny.
The maturational changes in expression
and activity of P-glycoprotein (P-gp) may
affect the ability of the neonate to efflux opi-
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oids from the central nervous system compartment back to the systemic circulation.
This may in part explain the higher sensitivity to central nervous system depressive effects of opioids in neonates. To quantify P-gp
expression and its ontogeny, post-mortem
samples (20 weeks fetal age to adults) were
immunostained for P-gp in endothelial cells
of the blood-brain barrier [56]. The authors
hereby documented a maturational expression in P-gp to reach adult levels beyond
3 months of age. This ontogenic pattern fits
quite well with the observations that P-gp
polymorphisms (ABCB1 polymorphism
rs9282564) were associated with a higher
risk of opioid-related respiratory depression
in children, but not anymore in adults, and
not yet in neonates [57]. Adding one copy of
the minor allele increased the odds of prolonged stay to the respiratory depression 4.7
fold. This suggests extensive placental P-gp
expression, confirmed by the observation
that fetal P-gp polymorphisms affect fetal
growth and birth weight [58]. Finally, and
to illustrate the complex interaction between
different covariates, Sistonen et al. [59]
documented that a genetic model combining the maternal risk genotypes in CYP2D6
and P-gp was significantly associated with
central nervous system depression in infants
(OR 2.68) and their mothers (OR 2.74) during maternal codeine intake.
Drug targets
Similar to drug transporters, the knowledge on the ontogeny of drug receptors or
drug targets is very limited. Again, a search
for concordance in early infancy for polymorphisms earlier documented in adults
hereby provides clinical information on the
phenotypic expression and activity. In the
field of analgesia, we retrieved mainly reports on polymorphisms of the µ-opioid receptor (OPRM1), sometimes in combination
with catechol-O-methyl transferase (COMT)
polymorphisms. The combination of both
(OPRM1/COMT) results in synergistic effects since the need for rescue morphine in
mechanically ventilated newborns was associated with both polymorphisms, resulting in
an OR of 5.12 in the OPRM1/COMT highrisk genotype [60]. This is line with findings
reported in children following adenotonsil-
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lectomy, since COMT polymorphisms also
played a significant role in the variation in
postoperative pain perception and postoperative morphine requirements in children [61].

Clinical practice and research:
in search for the Holy Grail
Effective pain management remains an
important indicator of the quality of care provided to neonates, but observations on neuroapoptosis and integration of newer techniques and compounds force caregivers to
reconsider the clinical and research aspects
of “effective” pain management.
In the clinical setting, a structured approach is needed. This is because there is
still a gap between what we know and how
we act [19, 62]. An effective approach (e.g.,
evidence-based practice for improving quality (EPIQ) initiative) has been described by
Dunbar et al. [63]. Twelve NICU’s collaborated to improve neonatal pain and sedation
practices. In essence, these units developed
and subsequently implemented evidencebased better practices for pain management
in neonates, using such an EPIQ approach
[63, 64]. At the start, all units introduced
changes through plan-do-study-act cycles
and verified their performance. Strategies
for implementing potentially better practices varied and units identified their barriers to implementation, developed tools for
improvement, and subsequently shared their
experience. This approach of collaborative
quality improvement techniques enhanced
local quality improvement efforts and resulted in effective implementation of potentially
better practices in all centers [65, 66]. Research to further improve the knowledge on
pain management is obviously also needed.
Using a bullet point approach, we suggest
that such a research agenda covers:
–– Robust pharmacodynamic outcome variables are needed [18]. The development
and validation of more sophisticated pain
assessment tools is needed. At present,
we measure at the level of pain expression and that is not equal to pain perception.
–– PK/PD information on new compounds
can be generated. However, pharmacovigilance and long-term outcome data
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are needed after perinatal exposure to analgesics. This should include, but cannot
be limited to, neurocognitive outcome [2,
7, 8, 22].
–– Clinicians, ethical committees and other
stakeholders should design dose-finding
studies aimed at improving adequate
(i.e., effective, no over- or underexposure) administration of analgesics in neonates. The animal experimental findings
on neuro-apoptosis force us to reconsider
drugs and doses currently administered in
NICUs across the world.
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